International Journal of Emerging Research in Applied Medical Sciences (IJERAMS)

Virtual Oncology: Digital Twins for Predicting Cancer Evolution, Therapeutic Response, and Clinical Outcomes

Dr. Anirudh Bose[1], Dr. Rachana Pillai[2], Dr. Vinay Rao[3]

[1]Professor,Department of Endocrinology, PSG Institute of Medical Sciences, Coimbatore, India.Anirudhbose79@gmail.com

[2]Associate Professor,Department of Pharmacology, PSG Institute of Medical Sciences, Coimbatore, India.Rachanapillai22@gmail.com

[3]Assistant Professor,Department of Radiology, PSG Institute of Medical Sciences, Coimbatore, India.Vinayrao85@gmail.com

ABSTRACT

Cancer remains one of the leading causes of morbidity and mortality worldwide despite significant advances in molecular diagnostics, targeted therapeutics, immunotherapy, and precision medicine. The remarkable biological heterogeneity of tumors, together with dynamic interactions among malignant cells, the immune system, and the tumor microenvironment, continues to limit accurate prediction of disease progression and individualized therapeutic response. Recent advances in artificial intelligence (AI), computational biology, systems medicine, mathematical modeling, and multimodal biomedical data integration have introduced virtual oncology through digital twin technology as a transformative framework for predictive precision medicine. A digital twin is a continuously evolving virtual representation of an individual patient that integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical information to simulate disease evolution and therapeutic outcomes. Unlike conventional predictive models that analyze isolated datasets, digital twins continuously synchronize with real-world patient data, enabling dynamic prediction of tumor progression, treatment efficacy, toxicity, recurrence, metastatic dissemination, and long-term clinical outcomes. Advances in machine learning, deep learning, multimodal foundation models, graph neural networks, reinforcement learning, agentic AI, and generative artificial intelligence have substantially accelerated development of virtual oncology ecosystems capable of supporting diagnosis, prognostic prediction, adaptive therapeutics, immunotherapy optimization, radiation planning, drug discovery, and clinical decision support. Despite remarkable progress, important challenges remain regarding interoperability, computational scalability, explainability, cybersecurity, ethical governance, regulatory validation, and equitable clinical implementation.This review provides a comprehensive overview of virtual oncology based on digital twin technology, emphasizing computational foundations, clinical applications, emerging innovations, and future perspectives for predicting cancer evolution and optimizing personalized clinical care.[1]

Keywords: Digital twins, Virtual oncology, Artificial intelligence, Precision oncology, Computational oncology, Personalized medicine, Machine learning, Clinical decision support, Predictive medicine, Systems biology.

Article History

Received: 10 December 2025**; Accepted:** 18 December 2025**; Published:** 28 December 2025

Citation

Bose A.,(2025).Virtual Oncology: Digital Twins for Predicting Cancer Evolution, Therapeutic Response, and Clinical Outcomes. *International Journal of Emerging Research in Applied Medical Sciences (IJERAMS), 1(5), 125-133.*

DOI: https://doi.org/10.65477/ijerams.v1.i5.16

1. Introduction

Cancer is a biologically dynamic disease characterized by genomic instability, epigenetic alterations, transcriptional dysregulation, immune heterogeneity, metabolic reprogramming, and continuous interactions within the tumor microenvironment. Although precision medicine has significantly improved cancer treatment through molecular diagnostics and targeted therapeutics, patients with apparently similar pathological diagnoses frequently experience markedly different disease progression, therapeutic responses, and long-term survival outcomes because of complex biological variability.[2]

Modern oncology generates enormous quantities of heterogeneous biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, electronic health records, and longitudinal clinical documentation. While each modality contributes valuable insight into tumor biology, integrating these continuously evolving datasets into individualized clinical decisions remains one of the greatest challenges in precision oncology.[3]

Artificial intelligence has emerged as a transformative technology capable of interpreting complex biomedical information. More recently, advances in computational biology and systems medicine have expanded beyond isolated predictive algorithms toward continuously evolving virtual representations of individual patients known as digital twins.[4]

Virtual oncology represents a new paradigm in cancer medicine in which digital twins continuously synchronize with biological patients, enabling prediction of disease evolution, therapeutic response, recurrence, toxicity, and clinical outcomes before they occur in real-world clinical practice. These intelligent virtual ecosystems have the potential to fundamentally transform personalized oncology through predictive, preventive, adaptive, and data-driven healthcare.[5]

2. Evolution of Virtual Oncology

The concept of virtual oncology originated through adaptation of digital twin technology from aerospace engineering and advanced manufacturing, where virtual replicas of complex physical systems were developed to monitor operational performance, predict failures, and optimize maintenance. Similar computational principles were subsequently introduced into healthcare for modeling physiological systems and chronic diseases.[6]

Early healthcare digital twins primarily focused on cardiovascular medicine, diabetes, orthopedic biomechanics, and critical care monitoring. Oncology rapidly emerged as one of the most promising applications because cancer requires continuous integration of imaging, pathology, molecular biology, genomics, laboratory investigations, treatment history, and longitudinal patient monitoring.

Rapid advances in artificial intelligence, cloud computing, multimodal learning, wearable technologies, and computational systems biology have transformed digital twins from static computational models into continuously evolving virtual oncology ecosystems capable of supporting precision cancer medicine across the entire disease trajectory.[7]

Today, virtual oncology extends beyond simple prediction by enabling simulation of complex biological processes, therapeutic interventions, immune interactions, and long-term clinical outcomes within patient-specific computational environments.[8]

3. Computational Architecture of Virtual Oncology

Virtual oncology systems consist of multiple interconnected computational layers that continuously exchange biomedical information to create adaptive virtual representations of individual patients. Rather than functioning as isolated predictive algorithms, digital twins integrate multimodal biomedical data, artificial intelligence, mechanistic simulation, and clinical decision support into unified computational ecosystems.[9]

The first computational layer acquires information from radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, medication history, treatment records, electronic health records, and patient-reported outcomes.

Advanced preprocessing pipelines subsequently harmonize heterogeneous datasets through image normalization, molecular standardization, feature extraction, natural language processing, temporal synchronization, and multimodal encoding.

Artificial intelligence algorithms then generate comprehensive patient-specific computational representations using deep learning, transformer architectures, graph neural networks, probabilistic reasoning, and multimodal foundation models.

Simulation engines continuously model tumor growth, metastatic dissemination, immune interactions, therapeutic response, toxicity, recurrence, and survival while adaptive visualization platforms provide clinicians with interactive decision-support dashboards that evolve alongside the biological patient.[10]

4. Artificial Intelligence as the Foundation of Virtual Oncology

Artificial intelligence serves as the computational engine that enables virtual oncology systems to function as continuously learning healthcare ecosystems. Machine learning algorithms identify statistical relationships among clinical variables and patient outcomes, supporting prediction of recurrence, therapeutic response, toxicity, and survival across diverse malignancies.[11]

Deep learning substantially expands predictive capability through automated extraction of complex features from radiological imaging, histopathological slides, genomic datasets, physiological monitoring, and longitudinal clinical records. Convolutional neural networks excel in medical image interpretation, whereas transformer architectures efficiently integrate multimodal biomedical information while preserving long-range contextual relationships.

Graph neural networks model biological interactions involving genes, proteins, signaling pathways, immune networks, metabolic processes, and therapeutic targets, enabling digital twins to represent cancer as an interconnected biological system rather than isolated molecular abnormalities.

Foundation models and generative AI further strengthen scalability by learning generalized biomedical representations that can subsequently be adapted across numerous oncology applications while continuously improving through incorporation of new clinical data.[12]

5. Multimodal Data Integration

The effectiveness of virtual oncology depends upon comprehensive integration of heterogeneous biomedical information into unified computational representations. Cancer biology cannot be adequately described using individual biomarkers because tumor behavior reflects interactions among molecular biology, anatomy, physiology, immune responses, environmental influences, and longitudinal clinical events.[13]

Radiological imaging contributes anatomical and functional characterization of tumor morphology, vascularity, metabolism, and disease progression. Digital pathology provides microscopic assessment of tissue architecture, cellular differentiation, stromal remodeling, angiogenesis, immune infiltration, and tumor heterogeneity.

Genomic sequencing identifies driver mutations, whereas transcriptomics, proteomics, metabolomics, immunomics, laboratory biomarkers, and wearable technologies provide complementary information regarding biological function, treatment tolerance, physiological status, and disease evolution.

Artificial intelligence harmonizes these multimodal datasets through shared computational representations, enabling continuously evolving virtual patients capable of supporting comprehensive precision oncology.[14]

6. Digital Twins for Predicting Cancer Evolution

Prediction of cancer evolution represents one of the defining capabilities of virtual oncology. Unlike conventional statistical models that generate static risk estimates, digital twins continuously simulate biological processes governing tumor progression using patient-specific molecular, pathological, radiological, and clinical information.[15]

Artificial intelligence models tumor growth kinetics, angiogenesis, immune interactions, metastatic dissemination, treatment resistance, and disease recurrence through continuously updated computational simulations. Sequential imaging examinations, laboratory investigations, pathology reports, genomic analyses, and wearable sensor data continuously refine these predictions as patient conditions evolve.

Such adaptive simulation enables clinicians to anticipate future disease trajectories before clinically significant deterioration occurs, thereby supporting earlier intervention and more effective personalized treatment strategies.[16]

7. Predicting Therapeutic Response

Perhaps the greatest clinical advantage of virtual oncology lies in predicting individualized therapeutic response before treatment initiation. Digital twins integrate imaging, pathology, genomics, laboratory biomarkers, treatment history, physiological monitoring, and clinical characteristics to simulate responses to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations.[17]

Simulation engines estimate tumor regression, recurrence probability, progression-free survival, treatment-related toxicity, resistance mechanisms, and long-term survival across multiple therapeutic scenarios. These virtual experiments enable clinicians to compare alternative treatment strategies while minimizing unnecessary patient risk.

Because digital twins continuously synchronize with new patient information throughout therapy, treatment recommendations evolve dynamically as biological conditions change, supporting adaptive precision medicine rather than static treatment protocols.

8. Digital Twins in Precision Diagnostics

Accurate diagnosis forms the cornerstone of personalized cancer care, and virtual oncology substantially enhances diagnostic precision through continuous integration of radiological imaging, computational pathology, molecular biology, laboratory investigations, and longitudinal clinical information.[18]

Artificial intelligence automatically detects malignant lesions, segments tumors, characterizes imaging phenotypes, analyzes whole-slide pathology images, predicts molecular biomarkers, and integrates clinical documentation into unified diagnostic frameworks.

Continuous synchronization between virtual and biological patients enables diagnostic models to update whenever new imaging studies, pathology reports, laboratory investigations, or genomic sequencing become available. This adaptive diagnostic capability improves disease classification, molecular characterization, staging, and individualized clinical assessment while supporting multidisciplinary oncology workflows.[19]

9. Digital Twins in Immunotherapy and Tumor Microenvironment Modeling

The tumor microenvironment plays a pivotal role in determining cancer progression and responsiveness to immunotherapy. Virtual oncology systems integrate genomic alterations, immunomic profiles, transcriptomics, radiological imaging, digital pathology, cytokine signaling, laboratory biomarkers, and longitudinal clinical information into comprehensive computational immune models capable of simulating patient-specific tumor–immune interactions.[20]

Artificial intelligence continuously evaluates tumor-infiltrating lymphocytes, immune checkpoint expression, stromal remodeling, inflammatory pathways, angiogenesis, and spatial cellular organization to estimate responsiveness to immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, bispecific antibodies, and adoptive cellular therapies.

These adaptive computational simulations enable clinicians to evaluate multiple immunotherapeutic strategies before treatment initiation while continuously refining predictions as new biological information becomes available throughout therapy.

10. Adaptive Precision Therapeutics

Digital twins enable adaptive precision therapeutics by continuously modifying treatment recommendations according to evolving patient biology. Rather than relying on static therapeutic protocols, virtual oncology systems integrate sequential imaging, pathology, laboratory investigations, wearable sensor data, medication history, and treatment outcomes to optimize individualized care.[21]

Artificial intelligence predicts recurrence probability, progression-free survival, overall survival, treatment-related toxicity, and mechanisms of therapeutic resistance while comparing chemotherapy, targeted therapy, endocrine therapy, radiation therapy, surgery, immunotherapy, and multimodal treatment combinations.

Continuous synchronization between virtual and biological patients enables adaptive treatment planning that evolves throughout the disease course, ensuring that therapeutic strategies remain aligned with changing tumor biology and patient health status.

11. Radiation Oncology and Surgical Simulation

Radiation therapy and surgery remain essential components of comprehensive cancer management. Virtual oncology significantly enhances both therapeutic modalities through patient-specific computational simulations that optimize planning before clinical intervention.

During radiation therapy, sequential imaging continuously updates digital twin models, allowing artificial intelligence to modify tumor contours, predict radiation sensitivity, optimize dose distribution, and adapt treatment plans according to evolving anatomical and biological characteristics.[22]

Within surgical oncology, three-dimensional virtual patients generated from multimodal imaging provide detailed visualization of tumor location, vascular anatomy, adjacent organs, and critical neurovascular structures. Artificial intelligence further predicts surgical complexity, estimates resection margins, simulates operative approaches, and forecasts postoperative complications, thereby improving precision and patient safety.

12. Drug Discovery and Virtual Clinical Trials

Virtual oncology extends beyond patient care into pharmaceutical research and clinical trial optimization. Artificial intelligence integrates molecular biology, systems pharmacology, genomics, proteomics, metabolomics, pathology, imaging, and patient-specific computational models to predict therapeutic efficacy, toxicity, resistance mechanisms, and optimal dosing strategies before laboratory or clinical evaluation.[23]

Generative AI further accelerates drug discovery through molecular design, protein interaction prediction, target identification, and synthetic biomedical data generation. Digital twins also facilitate virtual clinical trials by enabling computational evaluation of therapeutic interventions, improving patient stratification, optimizing eligibility assessment, and supporting adaptive trial design.

These computational innovations have the potential to reduce development costs while accelerating translation of novel anticancer therapies into routine clinical practice.

13. Real-Time Clinical Decision Intelligence

One of the defining characteristics of virtual oncology is its ability to provide real-time clinical intelligence throughout diagnosis, treatment, and survivorship. Digital twin ecosystems continuously integrate radiological imaging, pathology reports, genomic sequencing, laboratory investigations, wearable sensor data, medication records, and longitudinal electronic health records into adaptive computational platforms.[24]

Interactive dashboards present individualized predictions regarding disease progression, therapeutic response, toxicity risk, recurrence probability, and long-term survival while allowing clinicians to compare multiple treatment scenarios before implementation.

Natural language processing further strengthens clinical workflows through automated summarization of physician notes, pathology reports, radiology reports, multidisciplinary tumor board discussions, and current scientific literature, thereby improving multidisciplinary communication and reducing administrative burden.

14. Explainable Artificial Intelligence, Ethics, and Clinical Implementation

Successful implementation of virtual oncology requires transparent, interpretable, and trustworthy artificial intelligence. Explainable AI (XAI) enables clinicians to understand how digital twins generate predictions through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual reasoning.[25]

Several important challenges remain. Large-scale virtual oncology systems require standardized multimodal datasets, interoperable healthcare infrastructures, secure computational platforms, and rigorous validation across diverse patient populations. Additional concerns include algorithmic bias, patient privacy, cybersecurity, informed consent, regulatory approval, medico-legal accountability, and equitable access to advanced computational technologies.

Addressing these issues will require multidisciplinary collaboration, standardized governance frameworks, prospective clinical validation, and transparent regulatory oversight before widespread clinical implementation.

15. Future Perspectives

The future of virtual oncology will likely involve increasingly sophisticated digital twin ecosystems capable of continuously integrating imaging, pathology, genomics, multi-omics, wearable biosensors, laboratory medicine, liquid biopsy, spatial biology, electronic health records, and real-world clinical outcomes into intelligent computational environments.[26]

Emerging technologies including multimodal foundation models, agentic artificial intelligence, reinforcement learning, federated learning, quantum computing, cloud-native healthcare infrastructure, Internet of Medical Things (IoMT), and generative AI are expected to substantially enhance predictive capability while improving scalability across healthcare systems.

Future virtual oncology platforms may function as continuously learning intelligent healthcare ecosystems capable of adaptive clinical reasoning, personalized therapeutic planning, automated workflow coordination, and evidence-based multidisciplinary decision support throughout the entire cancer care continuum.

16. Discussion

Virtual oncology represents one of the most significant paradigm shifts in computational medicine by transforming digital twin technology into continuously evolving intelligent healthcare ecosystems capable of predicting cancer evolution, therapeutic response, and clinical outcomes. Unlike conventional predictive algorithms that analyze isolated datasets, digital twins continuously synchronize with biological patients while integrating multimodal biomedical information into adaptive computational simulations.[27]

Applications spanning diagnosis, immunotherapy, radiation oncology, surgery, drug discovery, clinical trial optimization, and real-time clinical decision support demonstrate the extraordinary potential of virtual oncology for improving personalized cancer management.

Nevertheless, successful implementation depends upon overcoming important scientific, technical, ethical, regulatory, and organizational challenges through explainable artificial intelligence, standardized interoperability, secure computational infrastructure, prospective validation studies, and close collaboration among clinicians, computer scientists, biomedical engineers, healthcare organizations, and regulatory agencies.[28]

17. Conclusion

Virtual oncology is redefining precision cancer medicine by creating continuously evolving digital twin ecosystems capable of integrating radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical information into intelligent computational representations of individual patients.[29]

Artificial intelligence enables these virtual patients to continuously simulate disease progression, therapeutic response, toxicity, recurrence, and survival while supporting adaptive clinical decision-making across diagnosis, treatment, follow-up, and survivorship. As multimodal foundation models, digital twins, agentic AI, federated learning, generative artificial intelligence, and cloud-native computational infrastructure continue to mature, virtual oncology is expected to become an integral component of future precision medicine.

Although important scientific, technical, ethical, and regulatory challenges remain, continued interdisciplinary collaboration will accelerate responsible clinical implementation of virtual oncology, ultimately transforming cancer care from a reactive discipline into a predictive, preventive, adaptive, and highly personalized model that improves clinical outcomes and quality of life for patients worldwide.[30]

18. References

1.Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

3.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

4.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

5.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

6.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

7.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

8.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

9.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

10.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM

FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

11.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

12.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

13.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

14.Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.

15.Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.

16.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

17.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

18.Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.

19.Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

20.Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.

21.Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.

22.Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.

23.Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.

24.Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

25.Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.

26.Wei, L. et al. (2023) ‘Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration’, British Journal of Radiology, 96(1150), Article 20230211.

27.Boehm, K.M. et al. (2022) ‘Harnessing Multimodal Data Integration to Advance

Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

28.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

29.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

30.Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.